Aralez Pharma (ARLZ) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ARLZ Hot Sheet
Join SI Premium – FREE
Aralez Pharma (NASDAQ: ARLZ) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $22.55 million.
GUIDANCE:
Aralez Pharma sees FY2017 revenue of $95-105 million, raised from prior range of $80-100 million.
Aralez Pharma sees FY2018 revenue of $140-160 million
For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- Top restaurant stocks to watch, according to Raymond James
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
